Naltrexone Implant
Opioid Use Disorder
Phase 1Active
Key Facts
About Delpor
Delpor is a private, clinical-stage biotech company pioneering once-yearly subcutaneous implant therapies for chronic diseases, with a primary focus on CNS disorders. Its proprietary, passive (non-mechanical) implant technology aims to improve patient adherence, safety, and efficacy by maintaining steady drug levels within a therapeutic window for up to a year. The company's most advanced program is a risperidone implant for schizophrenia, which has completed a Phase 1b/2a study, and it has also initiated a Phase 1 trial for a naltrexone implant for opioid addiction. Delpor's business model is centered on developing and commercializing novel therapeutic products enabled by its delivery platform.
View full company profileTherapeutic Areas
Other Opioid Use Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| TRV734 | Trevena | Phase 1 |
| FP-004 (SIF Formulation) | Foresee Pharmaceuticals | Preclinical |
| Vaxine Opioid Addiction Vaccine | Vaxine | Preclinical |
| Safer Ibogaine Analogs | Gilgamesh Pharmaceuticals | Pre-clinical/Research |
| AM-510 | Aion Medicines | Discovery |
| Platform Expansion | Amygdala Neurosciences | Research |
| Undisclosed OUD Program | Epiodyne | Pre-clinical |
| AQL™-Naltrexone | Plumb Pharmaceuticals | Pre-clinical |
| MEB-1170 | Mebias Discovery | Phase 1 |
| SUBLOCADE® | Indivior PLC | Marketed |